PPD Aquires Excel PharmaStudies

PPD has completed its acquisition of Excel, a contract research organisation in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions it to capitalise on the growth of the outsourcing market in Asia Pacific.

With this acquisition, PPD has expanded its capability to offer Phase II-IV clinical management, data management, biostatistics, regulatory and quality assurance services under a variety of operating models, ranging from functional to full service. Excel will continue to operate under its brand with full access to PPD’s global resources, clients and expertise.

David Grange, chief executive officer of PPD, said: “China is a strong, emerging area for clinical research as evidenced by its 21 percent compounded annual growth rate over the past five years. Excel brings an expansive range of services, broad client base and deep regulatory experience, which provide PPD additional capacity and expertise in this growing region.

“We look forward to sharing more about our expanded presence in Asia Pacific at the CHINATRIALS conference next week.”